Pneumococcal Infections: Clinical Trials

264 completed, 25 unknown, 22 recruiting, 11 active not recruiting. 122 Phase 3, 61 Phase 1, 47 Phase 2, 45 Phase 4, 21 Not applicable.

By phase and status

Phase	Trials	Status
Phase 3	122	Completed 105, Recruiting 9, Active not recruiting 4, Unknown 4
Phase 1	61	Completed 49, Unknown 5, Recruiting 4, Active not recruiting 1, Not yet recruiting 1, Terminated 1
Phase 2	47	Completed 39, Active not recruiting 3, Recruiting 2, Terminated 2, Withdrawn 1
Phase 4	45	Completed 32, Recruiting 5, Unknown 4, Terminated 3, Active not recruiting 1
Not applicable	21	Completed 13, Unknown 5, Enrolling by invitation 1, Recruiting 1, Withdrawn 1
Early Phase 1	3	Completed 2, Active not recruiting 1

Follow Pneumococcal Infections: new trials by email Literature Review of Pneumococcal Infections trials Research Report on Pneumococcal Infections

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Randomized Controlled Trial Of Text Messages To Increase Pneumococcal Vaccination In Adults In Chile. WhatsApp text message reminder for pneumococcal vaccination - Pneumococcal Infections, Immunization Programs	Not applicable	Enrolling by invitation	Pablo Tomás Valenzuela García	40753	2026-10-01	2026-10-22
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC) - Pneumococcal Disease	Phase 3	Recruiting	Pfizer	4670	2026-09-08	2026-10-14
A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) Previously vaccinated with PCV13 (CanSino), Previously vaccinated with PCV13 (Pfizer) - Pneumococcal Infections, Streptococcal Infections		Not yet recruiting	CanSino Biologics Inc.	100	2026-09-01	2026-08-05
A Study to Evaluate 20vPnC in Healthy Chinese Infants 20vPnC, 13vPnC - Pneumococcal Diseases	Phase 3	Recruiting	Pfizer	1250	2026-07-25	2026-08-10
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines Pneumococcal Vaccine - Vaccine, Pneumococcal Disease	Phase 4	Recruiting	University of Alabama at Birmingham	70	2026-07-01	2026-08-21
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease	Phase 3	Recruiting	Pfizer	1200	2026-06-15	2026-10-26
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease	Phase 3	Recruiting	Pfizer	3230	2026-05-29	2026-10-20
Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M) - Streptococcus Pneumoniae Infection	Phase 1 / Phase 2	Recruiting	CanSino Biologics Inc.	854	2026-05-24	2026-08-05
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease	Phase 3	Recruiting	Pfizer	2400	2026-05-04	2026-10-26
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination 31-valent pneumococcal conjugate vaccine, PCV20 - Pneumococcal Vaccines	Phase 3	Active not recruiting	Vaxcyte, Inc.	752	2026-02-09	2026-06-30
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age PCV21 vaccine, 20vPCV licensed vaccine - Pneumococcal Immunization, Healthy Volunteers	Phase 3	Recruiting	Sanofi	2195	2026-01-20	2026-10-05
Opportunistic Pneumococcal Immunisation Trial in MALnutrition Pneumococcal conjugate vaccine, Typhoid conjugate vaccine - Severe Acute Malnutrition in Childhood, Pneumococcal Disease	Phase 4	Recruiting	Nick Fancourt	214	2026-01-16	2026-10-08
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1) - Pneumococcal Infection	Phase 1	Recruiting	Merck Sharp & Dohme LLC	210	2026-01-13	2026-10-02
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo - Pneumococcal Vaccines	Phase 3	Active not recruiting	Vaxcyte, Inc.	1390	2026-01-12	2026-06-30
Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults Early intervention, Delayed intervention - Acute Febrile Illness, Pneumococcal Infections	Phase 4	Recruiting	Centre Hospitalier Universitaire de Saint Etienne	1052	2025-12-17	2026-03-30
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 - Pneumococcal Disease	Phase 3	Completed	Vaxcyte, Inc.	4049	2025-12-01	2026-10-16
Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years Sinovac PCV24, Prevnar® - Pneumococcal Infectious Disease	Phase 2	Recruiting	Sinovac Life Sciences Co., Ltd.	420	2025-11-25	2025-12-24
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) PCV13i, Prevnar 13 - Pneumococcal Infections, Streptococcal Infections	Phase 3	Active not recruiting	CanSino Biologics Inc.	600	2025-11-14	2026-08-05
Serum Collection Study for Assay Development Gamma-PN - Pneumococcal Disease, Invasive, Pneumococcal Disease	Phase 1	Recruiting	GPN Vaccines	12	2025-10-01	2025-10-03
PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13) - Pneumococcal Infectious Disease	Phase 2	Completed	Reinovax Biologics Co., LTD	480	2025-09-11	2026-07-27

Showing 20 of 336. Sign in to see all of them.

Narrower conditions

Pneumonia, Pneumococcal (44)  ·  Streptococcal Infections (30)  ·  Pneumonia (25)  ·  HIV Infections (12)  ·  Influenza, Human (10)  ·  Community-Acquired Pneumonia (8)  ·  Acquired Immunodeficiency Syndrome (7)  ·  Meningococcal Infections (7)  ·  Otitis Media (7)  ·  Diphtheria (6)  ·  Pneumonia, Bacterial (6)  ·  Tetanus (6)  ·  Bacterial Infections (4)  ·  Hepatitis B (4)

Broader conditions

Bacterial Infections and Mycoses (336)  ·  Gram-Positive Bacterial Infections (335)  ·  Infections (333)  ·  Bacterial Infections (332)  ·  Streptococcal Infections (306)  ·  Respiratory Tract Diseases (82)  ·  Respiratory Tract Infections (79)  ·  Lung Diseases (71)  ·  Pneumonia (45)  ·  Pneumonia, Bacterial (42)  ·  Virus Diseases (36)  ·  RNA Virus Infections (33)  ·  Immune System Diseases (24)  ·  Blood-Borne Infections (18)

Interventions

13-valent pneumococcal vaccine (61)  ·  Pneumococcal Vaccines (36)  ·  23-valent pneumococcal capsular polysaccharide vaccine (35)  ·  Heptavalent Pneumococcal Conjugate Vaccine (34)  ·  PHiD-CV vaccine (15)  ·  diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (12)  ·  Sodium Chloride (10)  ·  Vaccines, Combined (7)  ·  Influenza Vaccines (6)  ·  RIX4414 vaccine (6)  ·  10-valent pneumococcal conjugate vaccine (5)  ·  2,4,5,4'-tetrachlorodiphenylsulfoxide (5)  ·  Blood Specimen Collection (5)  ·  Hepatitis A Vaccines (5)  ·  Hiberix (5)

Sponsors

Pfizer (62)  ·  Merck Sharp & Dohme LLC (46)  ·  GlaxoSmithKline (31)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (16)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (9)  ·  Sinovac Life Sciences Co., Ltd. (7)  ·  Assistance Publique - Hôpitaux de Paris (6)  ·  Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (5)  ·  CanSino Biologics Inc. (5)  ·  PATH (5)  ·  Sinovac Biotech Co., Ltd (5)  ·  Vaxcyte, Inc. (5)  ·  GPN Vaccines (4)  ·  Korea University Guro Hospital (4)  ·  Public Health England (4)

Countries

United States (92)  ·  China (43)  ·  France (27)  ·  Spain (19)  ·  Poland (18)  ·  South Korea (18)  ·  Australia (17)  ·  Finland (17)  ·  Japan (16)  ·  Puerto Rico (15)  ·  Canada (13)  ·  Germany (13)  ·  United Kingdom (12)  ·  Taiwan (11)  ·  Thailand (11)

Top investigators

Du Lin, Master (3)  ·  Amanda J Leach, PhD (2)  ·  Edward K Mulholland, DM (2)  ·  Edward N Janoff, MD (2)  ·  Elizabeth Coates, PhD (2)  ·  Francesca Montagnani, MD, PhD (2)  ·  Hee Jin Cheong, MD, PhD (2)  ·  Jonathan R Carapetis, PhD (2)  ·  Kai Chu (2)  ·  Matthieu Groh, MD, MSc (2)

Results publications

PMID 11115712, PMID 1347058, PMID 24086113, PMID 25008901, PMID 2572650, PMID 25785969, PMID 30689507, PMID 3183430, PMID 36211411, PMID 36368038, PMID 3652522, PMID 37846456, PMID 41187484, PMID 10762563, PMID 11172176, PMID 14557958, PMID 14722149, PMID 14998500, PMID 15188713, PMID 15356783, PMID 15882530, PMID 15995950, PMID 16390959, PMID 16567982, PMID 17156899, PMID 17173226, PMID 17197876, PMID 17391816, PMID 17541638, PMID 17938165, PMID 18470901, PMID 18477402, PMID 18676537, PMID 18799552, PMID 19091990, PMID 19196675, PMID 19325447, PMID 19325451, PMID 19325452, PMID 19522655, PMID 19584345, PMID 19663708, PMID 19782998, PMID 19906895, PMID 20010312, PMID 20088694, PMID 20199764, PMID 20206670, PMID 20234331, PMID 2025948

NIH funding

2018 (14), 2019 (8), 2014 (3), 2017 (3), 2023 (3), 2025 (3), 2009 (2), 2015 (2), 2016 (1), M01RR000030 (1), M01RR000032 (1), M01RR000039 (1), M01RR000044 (1), M01RR000070 (1), M01RR000633 (1)